<?xml version='1.0' encoding='utf-8'?>
<document id="9690942"><sentence text="Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase."><entity charOffset="0-10" id="DDI-PubMed.9690942.s1.e0" text="Sorivudine" /><entity charOffset="15-29" id="DDI-PubMed.9690942.s1.e1" text="5-fluorouracil" /><entity charOffset="99-116" id="DDI-PubMed.9690942.s1.e2" text="dihydropyrimidine" /><pair ddi="false" e1="DDI-PubMed.9690942.s1.e0" e2="DDI-PubMed.9690942.s1.e0" /><pair ddi="false" e1="DDI-PubMed.9690942.s1.e0" e2="DDI-PubMed.9690942.s1.e1" /><pair ddi="false" e1="DDI-PubMed.9690942.s1.e0" e2="DDI-PubMed.9690942.s1.e2" /><pair ddi="false" e1="DDI-PubMed.9690942.s1.e1" e2="DDI-PubMed.9690942.s1.e1" /><pair ddi="false" e1="DDI-PubMed.9690942.s1.e1" e2="DDI-PubMed.9690942.s1.e2" /></sentence><sentence text="Sorivudine (1-beta-D-arabinofuranosyl-E-5-[2-bromovinyl] uracil; BV-araU; SQ32,756) is an antimetabolite which is a synthetic analogue of thymidine"><entity charOffset="0-10" id="DDI-PubMed.9690942.s2.e0" text="Sorivudine" /><entity charOffset="12-63" id="DDI-PubMed.9690942.s2.e1" text="1-beta-D-arabinofuranosyl-E-5-[2-bromovinyl] uracil" /><entity charOffset="65-72" id="DDI-PubMed.9690942.s2.e2" text="BV-araU" /><entity charOffset="138-147" id="DDI-PubMed.9690942.s2.e3" text="thymidine" /><pair ddi="false" e1="DDI-PubMed.9690942.s2.e0" e2="DDI-PubMed.9690942.s2.e0" /><pair ddi="false" e1="DDI-PubMed.9690942.s2.e0" e2="DDI-PubMed.9690942.s2.e1" /><pair ddi="false" e1="DDI-PubMed.9690942.s2.e0" e2="DDI-PubMed.9690942.s2.e2" /><pair ddi="false" e1="DDI-PubMed.9690942.s2.e0" e2="DDI-PubMed.9690942.s2.e3" /><pair ddi="false" e1="DDI-PubMed.9690942.s2.e1" e2="DDI-PubMed.9690942.s2.e1" /><pair ddi="false" e1="DDI-PubMed.9690942.s2.e1" e2="DDI-PubMed.9690942.s2.e2" /><pair ddi="false" e1="DDI-PubMed.9690942.s2.e1" e2="DDI-PubMed.9690942.s2.e3" /><pair ddi="false" e1="DDI-PubMed.9690942.s2.e2" e2="DDI-PubMed.9690942.s2.e2" /><pair ddi="false" e1="DDI-PubMed.9690942.s2.e2" e2="DDI-PubMed.9690942.s2.e3" /></sentence><sentence text=" This drug has demonstrated antiviral activity against varicella zoster virus, herpes simplex type 1 virus, and Epstein-Barr virus" /><sentence text=" Clinical studies in Japan and subsequently worldwide showed this drug to be a potent agent for treating varicella zoster infections" /><sentence text=" Although in general well tolerated, a fatal drug interaction with fluoropyrimidine drugs was subsequently observed"><entity charOffset="67-83" id="DDI-PubMed.9690942.s5.e0" text="fluoropyrimidine" /></sentence><sentence text=" While three deaths resulting from this interaction were recognized to have occurred during the initial clinical evaluation in Japan, the full impact of the interaction was not recognized in Japan until post-marketing when an additional 23 cases of severe toxicity were reported including 16 patients who subsequently died from fluoro-pyrimidine toxicity"><entity charOffset="328-345" id="DDI-PubMed.9690942.s6.e0" text="fluoro-pyrimidine" /></sentence><sentence text=" Worldwide recognition of this potentially fatal drug-drug interaction led to subsequent disapproval in the US and elsewhere" /><sentence text=" The interaction has been shown to be due to suppression of 5-fluorouracil (5-FU) catabolism, resulting in higher levels of 5-FU than would normally be observed"><entity charOffset="60-74" id="DDI-PubMed.9690942.s8.e0" text="5-fluorouracil" /><entity charOffset="76-80" id="DDI-PubMed.9690942.s8.e1" text="5-FU" /><entity charOffset="124-128" id="DDI-PubMed.9690942.s8.e2" text="5-FU" /><pair ddi="false" e1="DDI-PubMed.9690942.s8.e0" e2="DDI-PubMed.9690942.s8.e0" /><pair ddi="false" e1="DDI-PubMed.9690942.s8.e0" e2="DDI-PubMed.9690942.s8.e1" /><pair ddi="false" e1="DDI-PubMed.9690942.s8.e0" e2="DDI-PubMed.9690942.s8.e2" /><pair ddi="false" e1="DDI-PubMed.9690942.s8.e1" e2="DDI-PubMed.9690942.s8.e1" /><pair ddi="false" e1="DDI-PubMed.9690942.s8.e1" e2="DDI-PubMed.9690942.s8.e2" /></sentence><sentence text=" The mechanism of this interaction is mediated through inhibition of the 5-FU rate-limiting catabolizing enzyme dihydropyrmidine dehydrogenase (DPD) by the BV-araU metabolite BVU"><entity charOffset="73-77" id="DDI-PubMed.9690942.s9.e0" text="5-FU" /><entity charOffset="112-128" id="DDI-PubMed.9690942.s9.e1" text="dihydropyrmidine" /><pair ddi="false" e1="DDI-PubMed.9690942.s9.e0" e2="DDI-PubMed.9690942.s9.e0" /><pair ddi="false" e1="DDI-PubMed.9690942.s9.e0" e2="DDI-PubMed.9690942.s9.e1" /></sentence><sentence text=" This drug-drug interaction of sorivudine and 5-FU further emphasizes the critical importance of DPD on the clinical pharmacology of 5-FU"><entity charOffset="31-41" id="DDI-PubMed.9690942.s10.e0" text="sorivudine" /><entity charOffset="46-50" id="DDI-PubMed.9690942.s10.e1" text="5-FU" /><entity charOffset="133-137" id="DDI-PubMed.9690942.s10.e2" text="5-FU" /><pair ddi="false" e1="DDI-PubMed.9690942.s10.e0" e2="DDI-PubMed.9690942.s10.e0" /><pair ddi="false" e1="DDI-PubMed.9690942.s10.e0" e2="DDI-PubMed.9690942.s10.e1" /><pair ddi="false" e1="DDI-PubMed.9690942.s10.e0" e2="DDI-PubMed.9690942.s10.e2" /><pair ddi="false" e1="DDI-PubMed.9690942.s10.e1" e2="DDI-PubMed.9690942.s10.e1" /><pair ddi="false" e1="DDI-PubMed.9690942.s10.e1" e2="DDI-PubMed.9690942.s10.e2" /></sentence><sentence text="" /></document>